SCHEMBL7251979

SCHEMBL7251979

COC(=O)c1cc(OC)c(OC)cc1NC(=O)/C=C(/C)c1ccc2ccsc2c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 8/20 0.47
HPGD P15428 3/20 0.47
POLB P06746 2/20 0.47
HSD17B10 Q99714 3/20 0.46
MAPK1 P28482 1/20 0.46
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.43
GAA P10253 5/20 0.43
HTT P42858 1/20 0.43
MAPT P10636 1/20 0.43
LTB4R Q15722 1/20 0.42
TERT O14746 3/20 0.42
GLA P06280 1/20 0.42
CTNNB1 P35222 1/20 0.41
WNT3A P56704 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4028328 0.92 TERT (0.49) KDM4EKMT2AALDH1A1HPGDHSD17B10
SCHEMBL7242175 0.85 TERT (0.56) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL7251982 0.85 TERT (0.43) KDM4EKMT2AALDH1A1HPGDHSD17B10
SCHEMBL6781951 0.83 KDM4E (0.60) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6781638 0.83 TERT (0.61) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6790891 0.82 KDM4E (0.59) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6786762 0.80 KDM4E (0.53) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL6787614 0.80 KDM4E (0.53) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL7248045 0.79 TERT (0.41) KDM4EKMT2AALDH1A1HPGDHSD17B10
SCHEMBL7241600 0.78 TERT (0.57) KDM4EKMT2AALDH1A1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660764-B2 Telomerase inhibitors such as trans-3-(benzothien-6-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide; use as antitumor agent BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-12-09 US disclosed
US-20020123509-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-09-05 US disclosed
WO-2002051830-A1 CARBOXAMIDES FOR USE AS TELOMERASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123509-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof ASS1, ADCY1, ADCY3 KDM4E 2061/4885KMT2A 2342/4885ALDH1A1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.